Oxford Therapeutics London

The GLP-1 Legacy

Life After Ozempic, Wegovy and Mounjaro

What Happens When The Medication Stops?

What happens after Ozempic, Wegovy or Mounjaro? For many people, the real challenge begins when the GLP-1 treatment pathways end. Appetite returns. Weight regain becomes a real risk. And most people are not prepared for what happens next.

The new book, The GLP-1 Legacy, was written to address this gap. It’s built on over 15,000 hours of one-to-one behavioural work in the weight-loss arena, including more than 100 in-depth interviews with GLP-1 users. The book also features a foreword by Professor Jane Ogden, Professor of Health Psychology at the University of Surrey.

View book on Amazon

After GLP-1s, that’s where the challenge begins

Appetite quickly returns, and food becomes more compelling, so maintaining your weight loss requires much more behavioural effort. The support that made weight loss feel manageable is no longer in place.

Top Two FAQs

The top two questions entered into search engines clearly identify the concerns of GLP-1 users.

Question 1. Will my appetite come back when I stop taking GLP-1s? Answer. Yes. And most people aren’t prepared for it.

Question 2. Is weight regain common?” Answer. Yes. Especially without a plan.

When Support Falls Away

GLP-1 treatments, such as Mounjaro, Ozempic and Wegovy, are intended to be combined with behavioural and lifestyle input alongside the medication. In practice, however, that level of structured guidance is often limited or, in some cases, almost non-existent. As a result, many users are turning to the internet for advice. It was this consistent pattern of anxious people searching for answers that led to the research, writing and publication of the new book The GLP-1 Legacy.

Get your copy on Amazon

About The GLP-1 Legacy

The GLP-1 Legacy was written to support users both during and after GLP-1 treatment, particularly as medication is reduced or stopped and more responsibility begins to shift back to the individual. The authors, Martin and Marion Shirran, explore the patterns, habits and psychological factors that influence how weight loss can be sustained once the medication is no longer doing the heavy lifting. The GLP-1 Legacy – Oxford Therapeutics.

Whether read during GLP-1 treatment or after it has stopped, the book focuses on helping changes become more sustainable. While appetite is reduced and food thoughts are quieter, it creates a window where those changes are easier to put in place. As one reviewer noted they wished they had read it earlier, when far less effort would have been required.

What the Book Explores

From our work with people using GLP-1s and the broader conversations around it, the same questions come up repeatedly:

How do I maintain this weight loss?
Is it actually possible to keep it off?
What happens when my appetite returns?
How long do the effects of the medication last after stopping?
Why does weight regain happen, even when I’m trying?
What habits really make a difference long term?

It also introduces emerging approaches such as tapering and microdosing strategies, helping readers think more carefully about how they transition away from medication, rather than stopping abruptly without a plan. The book explores the interaction among biology, behaviour and the environment, and outlines practical approaches to sustaining progress. Built on 15,000+ hours of behavioural work and insights from 100+ GLP-1 users.

Clinical Perspective

The book includes a foreword by Professor Jane Ogden, Professor of Health Psychology at the University of Surrey, whose work has significantly contributed to the understanding of eating behaviour and long-term weight management. Her involvement provides an academic perspective on the behavioural challenges associated with weight maintenance after GLP-1 treatment.

Why Maintenance Matters

GLP-1 medications are proving highly effective for supporting weight loss. However, they do not in themselves establish the habits, routines or cognitive patterns required for long-term maintenance. When medication is reduced or withdrawn, appetite returns and the behavioural drivers that influenced eating before treatment often reappear. Without preparation, many former users find themselves managing the same challenges as before, but now without the support of the medication. This is where weight regain most often begins.

Understanding and preparing for this post-GLP-1 phase is central to maintaining outcomes and protecting the progress that has already been achieved. The pages on this website provide an overview of The GLP-1 Legacy, including a detailed introduction to the authors and an expanded synopsis.

GLP-1 Legacy – Oxford Therapeutics

For clinicians working within limited consultation time, the book provides a practical resource that patients can use independently, both during their weight-loss journey and as they transition off the medication. It is increasingly being recommended by healthcare professionals as a tool to support patients beyond prescribing, particularly at the point where behavioural strategies become critical to maintaining results.

Intended Audience

This site and the book are intended for:

individuals who are using or have used GLP-1 medications and wish to maintain their weight loss
healthcare professionals seeking a behaviourally informed resource to support patients during and after treatment

FDA

In the United States, the Food and Drug Administration (FDA) has mandated that GLP-1 receptor agonist weight-loss medications be prescribed in conjunction with a behavioural change programme. The FDA’s approach aims to ensure that patients not only lose weight but also adopt healthier lifestyle habits, which is crucial for maintaining their weight loss in the long term. This regulatory stance underscores the necessity of a comprehensive treatment plan, as detailed on the pages of this website.

NICE

Similarly, the National Institute for Health and Care Excellence (NICE) in the United Kingdom advocates a multifaceted approach to weight management. NICE recommends that weight-loss medications, including Ozempic, Wegovy and Mounjaro, be integrated into a comprehensive weight management programme. The Guidance from Nice emphasises the importance of addressing obesity through a holistic and sustainable approach, aiming to deliver long-term health benefits and improved quality of life for patients. Marion Shirran, the co-founder of Oxford Therapeutics Ltd and the co-author of The GLP-1 Legacy, is a NICE stakeholder and a member of the All-Party Parliamentary Group on Obesity.

Get your copy on Amazon

Is weight regain inevitable after GLP-1 treatment?

No. While weight regain is common, it is not inevitable. Many people maintain their weight loss by putting structure in place as the medication is reduced or stopped.

Why is the transition off GLP-1 medications so challenging?

GLP-1 medications regulate appetite while they are being used. When they are reduced or stopped, that support is removed. This creates a gap between weight loss and maintenance, where behaviour becomes more important.

How quickly does appetite return after stopping GLP-1 medications?

Appetite usually returns gradually over a period of weeks, although the timing differs between individuals. As hunger increases, food becomes more noticeable and behaviour can begin to shift.

What happens after stopping Ozempic, Wegovy or Mounjaro?

After stopping GLP-1 medications, appetite typically begins to return and maintaining weight loss requires more conscious effort. This transition phase is where many people experience changes in eating patterns and behaviour.

What is The GLP-1 Legacy and how does it help?

The GLP-1 Legacy is a practical, behaviour-focused resource designed to support the transition phase after GLP-1 treatment. It helps individuals understand appetite changes, manage behavioural challenges and maintain weight loss once medication is reduced or stopped.

How much weight do you regain after GLP-1 medications?

Weight regain varies, but research shows that a proportion of lost weight often returns after stopping treatment. The amount depends largely on how the transition phase is managed.

If you’re looking to understand what happens after stopping Ozempic, Wegovy or Mounjaro, these popular guides cover the questions most people are asking right now. From how quickly appetite returns and what drives weight regain, to practical ways of maintaining control without medication, each guide is based on real-world behavioural experience. Start with our detailed breakdown of what happens after stopping GLP-1 medications, explore how much weight regain to expect, and learn how quickly appetite returns after Ozempic. You can read our post about what happens after coming off GLP-1s.You can also read about how long GLP-1 medications stay in your system, practical strategies for maintaining weight loss after Wegovy, and our guide to microdosing and tapering GLP-1 injections for a more gradual transition.